[Table_StockInfo] 买入 2024年 04月 30日 （维持） 证券研究报告•2023年年报&2024年一季报点评 当前价： 19.26元 爱 柯 迪（600933） 汽车 目标价： ——元（6个月） “产品超市”品类持续完善，全球布局有序推进 投资要点 西南证券研究发展中心 [T a事ble件_S：（u1m）公ma司ry发] 布2023年度报告，2023年实现营收59.57亿元，同比+39.67%； [分Ta析bl师e_：Au郑th连or声] 归母净利润9.13亿元，同比+40.84%；扣非归母净利润8.76亿元，同比+45.15%。 执业证号：S1250522040001 其中，2023Q4实现营收17.23亿元，同环比分别+39.05%/ +8.25%；归母净利 电话：010-57758531 润 3.16亿元，同环比分别+30.94%/ +56.52%；扣非归母净利润2.87亿元，同 邮箱：zlans@swsc.com.cn 环比分别+39.38%/ +44.18%。（2）公司发布2024年一季度报告，2024Q1实现 联系人：冯安琪 营收 16.42亿元，同环比分别+30.69%/ ...

Investment Rating - The report maintains a positive outlook on Fibro, indicating a strong growth trajectory and confidence in the company's future through stock incentive plans [4][10]. Core Insights - FibroGo's per-use charging model and the launch of the new drug Resmetirom for MASH are expected to significantly expand the demand for liver fibrosis testing [2][11]. - The company reported a revenue of 1.15 billion yuan in 2023, a 14.4% increase year-on-year, with a net profit of 100 million yuan, up 3.8% [3][5]. - The first quarter of 2024 showed a remarkable revenue growth of 33.4% to 320 million yuan, with net profit soaring by 228.6% to 40 million yuan [3][5]. Summary by Sections Financial Performance - In 2023, the revenue breakdown shows medical device income at 830 million yuan (+35.4%), while pharmaceutical income decreased to 280 million yuan (-20.8%) [3][5]. - The company expects revenue growth for 2024-2026 to be 34.3%, 36.2%, and 30.2% respectively, with net profit projected to grow significantly [5][11]. Business Segments - The medical device segment is anticipated to continue its strong performance, with a projected gross margin of 90% for 2024-2026 [11][12]. - The pharmaceutical segment is transitioning to an academic-led sales model, with expected revenue growth of 18% annually from 2024 to 2026 [11][12]. Stock Incentive Plan - The company has proposed a stock incentive plan to grant approximately 3.5 million shares, representing 1.3% of the total share capital, with performance targets set for net profit over the next three years [4][10]. Market Outlook - The global market for liver fibrosis testing is expected to expand due to the new per-use charging model and the introduction of new drugs targeting MASH [2][11].

风险提示：终端市场需求波动风险、海外市场风险、核心设备依赖外采风险、 在建产能建成及达产进度不及预期风险。 [Table_QuotePic] 相对指数表现 单位：百万元 2023A 2024E 2025E 2026E 3）数字化缝纫设备为 TEXPA 产品，目前处于市场开发初期，有望快速放量，同时在起量 后毛利率将快速提高。预计 2024-2026 年 TEXPA 订单同比增长 50%、20%、15%，毛利率分 别为 25%、28%、30%。 请务必阅读正文后的重要声明部分 2 请务必阅读正文后的重要声明部分 3 投资评级说明 | --- | --- | --- | --- | |----------|----------------|-------|---------------------------------------------------------------------| | | | | | | | | | | | 行业评级 | 跟随大市：未来 | 6 | 个月内，行业整体回报介于同期相关证券市场代表性指数 -5% 与 5% 之间 | | | 弱于大市：未来 | | 个月内，行业整体回报低于 ...

Investment Rating - The report assigns a "Buy" rating for the company with a target price of 25.00 CNY over the next six months [1]. Core Insights - The company has shown significant growth in revenue and profit, with a 2023 revenue of 14.1 billion CNY, a 21.9% increase year-on-year, and a net profit of 1.6 billion CNY, recovering from a loss in the previous year [50]. - The company is positioned as a leading player in the industrial automation sector, particularly in the energy industry, benefiting from the domestic push for self-controlled systems in power generation [27][28]. - The company has a strong order pipeline, with multiple contracts secured for DCS system projects, indicating an acceleration in demand [8][50]. Financial Performance - Revenue growth is projected to continue, with expected revenues of 19.0 billion CNY in 2024 (+35.0%), 24.4 billion CNY in 2025 (+28.6%), and 30.5 billion CNY in 2026 (+24.7%) [34]. - The net profit forecast for 2024 is 2.4 billion CNY (+49.9%), followed by 3.1 billion CNY in 2025 (+29.4%) and 4.0 billion CNY in 2026 (+27.4%) [34]. - The company's EPS is expected to be 1.00 CNY in 2024, 1.30 CNY in 2025, and 1.66 CNY in 2026, with corresponding dynamic PE ratios of 16, 12, and 10 [34][68]. Business Overview - The company has over 30 years of experience in the industrial automation and information technology sectors, providing a comprehensive range of products and solutions including DCS, PLC, industrial robots, and real-time databases [4][6]. - The company has established a robust incentive mechanism to align the interests of management and shareholders, enhancing team motivation and cohesion [5]. - The company is actively expanding its international presence, with projects in countries such as Pakistan, Dubai, and Hungary, enhancing its brand influence in overseas markets [30]. Market Position - The company is recognized as a top-tier provider of DCS systems in China, with a significant market share in the power generation sector, particularly in the context of increasing domestic demand for self-controlled systems [27][28]. - The company has successfully transitioned to a fully self-controlled system, the NT6000, which has been certified by relevant authorities and implemented in major projects [55]. Future Outlook - The company is well-positioned to capitalize on the ongoing trends in industrial automation and digital transformation, with a focus on intelligent manufacturing and the integration of AI technologies [30]. - The anticipated growth in the industrial automation sector, driven by government initiatives such as "Industry 4.0" and "Made in China 2025," presents significant long-term growth opportunities for the company [30].

Investment Rating - The report maintains a "Buy" rating for the company [1] Core Views - The company achieved a revenue of 5.96 billion yuan in 2023, representing a year-on-year growth of 16.1%, and a net profit of 1.72 billion yuan, up 11.0% year-on-year. In Q4 2023, revenue was 1.52 billion yuan, with a year-on-year increase of 10.4%, and net profit was 370 million yuan, up 7.0% year-on-year. For Q1 2024, revenue reached 1.77 billion yuan, a year-on-year growth of 11.1%, and net profit was 590 million yuan, up 10.0% year-on-year, aligning with market expectations [2][3] Summary by Sections Financial Performance - In 2023, the company’s revenue from high-end, mid-range, and low-end liquor was 5.68 billion yuan (+16.6%), 80 million yuan (-19.8%), and 90 million yuan (+0.7%) respectively. Overall sales volume and price per ton increased by 7.4% and 7.6% respectively. The company plans to launch new products to enhance product structure [2][3] - For Q1 2024, the company reported a gross margin of 76.5%, with a net profit margin of 33.3%. The cash flow remains stable, with cash receipts of 1.4 billion yuan, up 15.5% year-on-year [2][3] Market and Product Strategy - The company is positioned to benefit from the upgrading of the Anhui liquor industry, with a focus on high-end products. The company aims to double sales volume and significantly increase the proportion of mid-to-high-end products in its portfolio by 2024 [2][3] - The company plans to enhance brand influence and market presence through strategic marketing and product launches, particularly focusing on the "Jian" series [2][3] Earnings Forecast - The earnings per share (EPS) for 2024-2026 are projected to be 2.87 yuan, 3.33 yuan, and 3.83 yuan respectively, with corresponding dynamic price-to-earnings (PE) ratios of 15, 13, and 11. The company is expected to maintain a high return on equity (ROE) of 18.94% in 2024 [2][3][10]

Investment Rating - The report does not provide a specific investment rating for the company [1] Core Views - The company's performance remains stable with continuous optimization of expenses [2] - Core businesses show highlights: - Respiratory therapy business revenue reached 3.37 billion yuan (+50.6%) in 2023, with key products like ventilators, oxygen concentrators, and nebulizers growing at +60%, +30%, and +60% respectively [2] - Diabetes care business revenue reached 730 million yuan (+37.1%) in 2023, with the new 14-day calibration-free CGM product CT3 expected to drive growth in 2024 [2] - Home electronics business revenue reached 1.67 billion yuan (+10.1%) in 2023, with electronic blood pressure monitors growing over 20% [2] - Infection control business revenue declined to 760 million yuan (-36.2%) in 2023 due to high base effects [2] - Emergency care business revenue reached 160 million yuan (+8.0%) in 2023, with the self-developed AED product M600 expanding globally [2] - Rehabilitation and clinical equipment business revenue declined to 1.22 billion yuan (-12.8%) in 2023, but products like wheelchairs and acupuncture needles maintained good growth [2] Financial Performance - 2023 revenue: 7.97 billion yuan (+12.3%), net profit: 2.4 billion yuan (+50.2%) [2] - 2024 Q1 revenue: 2.23 billion yuan (-17.4%), net profit: 660 million yuan (-7.6%) [2] - 2023 gross margin: 51.5% (+3.4pp), net margin: 29.8% (+7.7pp) [2] - Expense ratios in 2023: sales 13.8% (-0.7pp), management 5.2% (-0.8pp), R&D 6.3% (-0.7pp), financial -2.0% (-0.6pp) [2] Strategic Direction - The company adheres to the strategy of "Innovation Reshaping Medical Devices" and focuses on three core sectors: respiratory, POCT, and infection control [3] - The company is also developing incubation businesses (emergency, ophthalmology, rehabilitation) and cornerstone businesses (blood pressure monitoring, temperature monitoring, TCM equipment, surgical instruments) while advancing internationalization [3] Business Projections - Revenue projections for 2024-2026: 9/10.3/11.9 billion yuan [3] - Net profit projections for 2024-2026: 2.3/2.6/3.0 billion yuan [3] - PE ratios for 2024-2026: 16/14/12x [3] Key Assumptions - Respiratory oxygen supply: Expected growth of 20% annually from 2024-2026, with gross margin of 56.5% [8] - Diabetes care: Expected growth of 30% annually from 2024-2026, with gross margin increasing from 63% to 67% [8] - Infection control solutions: Expected growth of 10% annually from 2024-2026, with gross margin of 50% [8] - Home electronic testing and IVD: Expected growth of 5% annually from 2024-2026, with gross margin of 50% [8] - Rehabilitation and clinical equipment: Expected stable growth from 2024-2026, with gross margin increasing from 34% to 35% [8] - Emergency care: Expected growth of 10% annually from 2024-2026, with gross margin of 32% [8] Financial Metrics - 2023 ROE: 19.94%, expected to stabilize around 16% from 2024-2026 [4] - 2023 EPS: 2.39 yuan, expected to grow to 2.98 yuan by 2026 [4] - 2023 PB: 3.12x, expected to decline to 2.02x by 2026 [4] - 2023 dividend yield: 1.63%, expected to range between 1.28%-1.41% from 2024-2026 [12]

[Table_StockInfo] 买入 2024年 4月 26日 （维持） 证券研究报告•2023年报及2024年一季报点评 当前价： 60.44元 通策医疗（600763） 医药生物 目标价： ——元（6个月） 经营逐渐企稳，静待拐点 投资要点 西南证券研究发展中心 [T ab业le绩_S总u结mm：a公ry司] 发布 2024年一季报和 2023年年报。2024年一季度实现收入 [分Ta析bl师e_：Au杜th向or阳] 7.1亿元（+5%），归母净利润1.7亿元（+2.5%），扣非后约1.7亿元（+4.2%）。 执业证号：S1250520030002 2023年公司实现收入28.5亿元（+4.7%），归母净利润5亿元（-8.7%），扣 电话：021-68416017 非后约4.8亿元（-8.4%）。 邮箱：duxy@swsc.com.cn  23年业绩承压，24年 Q1业绩符合预期。公司2023年收入同比增长4.7%，净 分析师：王钰畅 利润增速-6.1%。24年一季度收入增速5%，净利润增速3.2%。2023年公司种 执业证号：S1250524010001 电话：021-68416017 植收入 ...

Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Views - The company achieved a revenue of 83.27 billion yuan in 2023, representing a year-on-year growth of 12.6%, and a net profit attributable to shareholders of 30.21 billion yuan, up 13.2% year-on-year [2] - The company plans to distribute a cash dividend of 46.7 yuan per 10 shares (including tax), with a payout ratio of 60% [2] - The first quarter of 2024 saw revenues of 34.83 billion yuan, a year-on-year increase of 11.9%, and a net profit of 14.05 billion yuan, up 12.0% year-on-year, aligning with market expectations [2] - The company has set a double-digit growth target for 2024, supported by strong performance in the first quarter and growth in specific product lines [2][8] Summary by Sections Financial Performance - In 2023, the company's product revenue reached 62.8 billion yuan, with a year-on-year growth of 13.5%, while sales volume and price per ton changed by +18.0% and -3.8% respectively [2] - The gross profit margin for 2023 increased by 0.4 percentage points to 75.8%, with a net profit margin of 37.9%, remaining stable compared to 2022 [2] - For Q1 2024, the gross profit margin remained stable year-on-year, while the net profit margin was 42.0% [2] Growth Strategy - The company actively optimized its channel structure, with revenue from distribution and direct sales reaching 45.99 billion yuan (+13.6%) and 30.46 billion yuan (+12.5%) respectively in 2023 [2] - The company aims to maintain a clear pricing strategy, reducing traditional distributor volumes by about 20% to support price increases and restore channel confidence [2][8] Earnings Forecast - The expected earnings per share (EPS) for 2024-2026 are projected to be 8.94 yuan, 10.05 yuan, and 11.42 yuan, respectively, with corresponding dynamic price-to-earnings (PE) ratios of 17x, 15x, and 13x [2][3] - The company is positioned as a leader in the high-end price segment, with a strong growth outlook and increased dividend payout enhancing its investment value [2][8]

Investment Rating - The report maintains a "Buy" rating for Xinhua Winshare (601811) [1] Core Views - Xinhua Winshare achieved a 2023 operating income of 11.87 billion yuan, up 8.6% YoY, with net profit attributable to shareholders of 1.58 billion yuan, up 13.1% YoY [1] - In Q1 2024, the company reported revenue of 2.47 billion yuan, up 7% YoY, but net profit attributable to shareholders decreased by 3.3% to 210 million yuan [1] - The company has a stable dividend policy, with a 2023 dividend yield of 5.2% for its H-shares [2] - The company is expected to benefit from the Western Development Strategy, potentially qualifying for a 15% corporate income tax rate [8] Business Performance Publishing Business - In 2023, the publishing business generated revenue of 2.99 billion yuan, up 8.8% YoY [42] - In Q1 2024, the publishing business achieved revenue of 890 million yuan, with 550 million yuan from textbooks and 250 million yuan from general books [42] - The company ranks 11th in market share among 37 publishing groups in China and 7th among local publishing groups [42] Distribution Business - In 2023, the distribution business achieved revenue of 10.49 billion yuan, up 5.5% YoY [19] - In Q1 2024, the distribution business generated revenue of 2.17 billion yuan, with 1.14 billion yuan from textbooks and 960 million yuan from general books [19] - The company is actively expanding into short video and live streaming e-commerce channels, with expected growth rates of 30%/25%/20% for 2024-2026 [7] Education Informatization - The company is focusing on education informatization, covering 6,190 schools and serving 4.662 million students through its "Wenxuan Youxue" online platform [19] Financial Forecasts - Revenue is expected to grow from 11.87 billion yuan in 2023 to 17.03 billion yuan in 2026, with a CAGR of 12.7% [9] - Net profit attributable to shareholders is forecasted to increase from 1.58 billion yuan in 2023 to 2.04 billion yuan in 2026 [21] - EPS is projected to rise from 1.28 yuan in 2023 to 1.65 yuan in 2026 [21] - The company's ROE is expected to remain stable at around 12% from 2023 to 2026 [21] Valuation - The company's PE ratio is forecasted to decrease from 11.45x in 2024 to 8.85x in 2026 [21] - The PB ratio is expected to decline from 1.38x in 2024 to 1.01x in 2026 [21]

Investment Rating - The report maintains a "Buy" rating for the company [1][4]. Core Views - The company reported Q1 2024 revenue of 1.86 billion yuan, a year-on-year increase of 24%, but a quarter-on-quarter decrease of 21.5%. The net profit attributable to the parent company was 210 million yuan, up 21.9% year-on-year but down 29.2% quarter-on-quarter [3]. - The company's gross margin was under pressure in Q1 2024, with a gross margin of 20.8%, down 0.7 percentage points year-on-year and 2.2 percentage points quarter-on-quarter. The net profit margin was 11.3%, down 0.4 percentage points year-on-year and 1.5 percentage points quarter-on-quarter. However, it is expected that gross margins will stabilize and recover as new projects ramp up and capacity utilization improves [3]. - The company is expanding its lightweight production capacity, with the first phase of a project in Mexico producing 4 million lightweight components annually, which commenced production at the end of Q3 2023. The second phase is expected to start production by the end of 2024. Additionally, the company has added 106 new projects in Q1 2024, including a lightweight project for a North American new energy vehicle company, projected to generate approximately 1.22 billion USD in total sales over five years [3]. - The company has accelerated its layout in the automotive steer-by-wire sector, with significant progress in the development of various steering systems. The sales volume of mechanical steering products increased by 54% year-on-year in Q1 2024 [3]. Summary by Sections Financial Performance - Q1 2024 revenue: 1.86 billion yuan, +24% YoY, -21.5% QoQ - Q1 2024 net profit: 210 million yuan, +21.9% YoY, -29.2% QoQ - Q1 2024 gross margin: 20.8%, -0.7pp YoY, -2.2pp QoQ - Q1 2024 net profit margin: 11.3%, -0.4pp YoY, -1.5pp QoQ [3][4]. Growth Projections - Expected EPS for 2024-2026: 2.61, 3.34, 4.21 yuan, with corresponding PE ratios of 22, 17, and 14 times. The CAGR for net profit attributable to the parent company is projected at 26.9% [4][5]. Capacity Expansion - The company is expanding its lightweight production capacity, with significant projects in Mexico and domestic production bases. The first phase in Mexico has commenced production, and the second phase is on track for late 2024 [3]. - New projects include a lightweight project for a North American new energy vehicle company and a platform project for a German joint venture, with significant projected sales [3]. Strategic Developments - The company has made strides in the steer-by-wire sector, with a focus on integrating control systems for various automotive applications. The sales of mechanical steering products have seen substantial growth [3].